Boston Reconciled Depreciation vs Non Operating Income Net Other Analysis
BSX Stock | USD 74.17 0.38 0.51% |
Boston Scientific financial indicator trend analysis is way more than just evaluating Boston Scientific Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Boston Scientific Corp is a good investment. Please check the relationship between Boston Scientific Reconciled Depreciation and its Non Operating Income Net Other accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boston Scientific Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
Reconciled Depreciation vs Non Operating Income Net Other
Reconciled Depreciation vs Non Operating Income Net Other Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Boston Scientific Corp Reconciled Depreciation account and Non Operating Income Net Other. At this time, the significance of the direction appears to have no relationship.
The correlation between Boston Scientific's Reconciled Depreciation and Non Operating Income Net Other is 0.01. Overlapping area represents the amount of variation of Reconciled Depreciation that can explain the historical movement of Non Operating Income Net Other in the same time period over historical financial statements of Boston Scientific Corp, assuming nothing else is changed. The correlation between historical values of Boston Scientific's Reconciled Depreciation and Non Operating Income Net Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Reconciled Depreciation of Boston Scientific Corp are associated (or correlated) with its Non Operating Income Net Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Operating Income Net Other has no effect on the direction of Reconciled Depreciation i.e., Boston Scientific's Reconciled Depreciation and Non Operating Income Net Other go up and down completely randomly.
Correlation Coefficient | 0.01 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Reconciled Depreciation
Non Operating Income Net Other
Most indicators from Boston Scientific's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Boston Scientific Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boston Scientific Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. At this time, Boston Scientific's Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 679.4 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.29 in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 8.1B | 8.7B | 9.9B | 10.4B | Total Revenue | 11.9B | 12.7B | 14.2B | 15.0B |
Boston Scientific fundamental ratios Correlations
Click cells to compare fundamentals
Boston Scientific Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Boston Scientific fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 30.6B | 30.8B | 32.2B | 32.5B | 35.1B | 36.9B | |
Short Long Term Debt Total | 10.3B | 9.5B | 9.5B | 9.3B | 9.5B | 10.0B | |
Other Current Liab | 2.8B | 3.0B | 3.0B | 2.7B | 3.2B | 3.4B | |
Total Current Liabilities | 4.9B | 3.7B | 4.3B | 3.8B | 4.9B | 5.2B | |
Total Stockholder Equity | 13.9B | 15.3B | 16.6B | 17.6B | 19.3B | 20.2B | |
Property Plant And Equipment Net | 2.4B | 2.5B | 2.7B | 2.8B | 3.3B | 3.5B | |
Net Debt | 10.1B | 7.8B | 7.5B | 8.4B | 8.6B | 9.1B | |
Retained Earnings | (2.3B) | (2.4B) | (1.4B) | (750M) | 819M | 860.0M | |
Accounts Payable | 542M | 513M | 794M | 862M | 942M | 989.1M | |
Non Current Assets Total | 25.9B | 24.1B | 25.9B | 26.7B | 28.6B | 30.1B | |
Non Currrent Assets Other | 735M | 545M | 563M | 707M | 679M | 713.0M | |
Net Receivables | 1.9B | 1.5B | 1.8B | 2.0B | 2.2B | 2.3B | |
Common Stock Shares Outstanding | 1.4B | 1.4B | 1.4B | 1.4B | 1.5B | 1.2B | |
Liabilities And Stockholders Equity | 30.6B | 30.8B | 32.2B | 32.5B | 34.9B | 36.6B | |
Non Current Liabilities Total | 11.8B | 11.8B | 11.3B | 11.1B | 10.7B | 6.2B | |
Inventory | 1.6B | 1.4B | 1.6B | 1.9B | 2.5B | 2.6B | |
Other Current Assets | 324M | 410M | 385M | 350M | 333M | 426.3M | |
Other Stockholder Equity | 15.8B | 17.5B | 17.7B | 18.0B | 18.4B | 10.0B | |
Total Liab | 16.7B | 15.5B | 15.6B | 14.9B | 15.6B | 8.6B | |
Property Plant And Equipment Gross | 2.4B | 2.5B | 2.3B | 2.4B | 6.8B | 7.1B | |
Total Current Assets | 4.7B | 6.7B | 6.3B | 5.8B | 6.5B | 3.3B | |
Accumulated Other Comprehensive Income | 270M | 207M | 263M | 269M | 49M | 51.5M | |
Short Term Debt | 1.4B | 13M | 261M | 20M | 531M | 417.5M | |
Intangible Assets | 7.9B | 5.9B | 6.1B | 5.9B | 6.0B | 4.9B | |
Other Liab | 3.0B | 2.2B | 2.1B | 1.8B | 2.1B | 1.9B | |
Other Assets | (2M) | 4.6B | 3M | 2M | (1M) | 950K | |
Long Term Debt | 8.6B | 9.1B | 8.8B | 8.9B | 8.6B | 5.6B | |
Good Will | 10.2B | 10.0B | 12.0B | 12.9B | 14.4B | 8.6B | |
Property Plant Equipment | 2.1B | 2.1B | 2.3B | 2.8B | 3.3B | 1.7B | |
Current Deferred Revenue | 144M | 138M | 208M | 220M | 266M | 333.1M | |
Net Tangible Assets | (4.2B) | 9.4B | (1.7B) | 11.7B | 13.4B | 14.1B | |
Retained Earnings Total Equity | (2.3B) | (2.4B) | (1.4B) | (750M) | (862.5M) | (905.6M) | |
Long Term Debt Total | 8.6B | 9.1B | 8.8B | 8.9B | 10.3B | 6.6B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boston Scientific Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Boston Stock analysis
When running Boston Scientific's price analysis, check to measure Boston Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boston Scientific is operating at the current time. Most of Boston Scientific's value examination focuses on studying past and present price action to predict the probability of Boston Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boston Scientific's price. Additionally, you may evaluate how the addition of Boston Scientific to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Transaction History View history of all your transactions and understand their impact on performance |
Is Boston Scientific's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Boston Scientific. If investors know Boston will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Boston Scientific listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.579 | Earnings Share 1.19 | Revenue Per Share 10.065 | Quarterly Revenue Growth 0.138 | Return On Assets 0.0454 |
The market value of Boston Scientific Corp is measured differently than its book value, which is the value of Boston that is recorded on the company's balance sheet. Investors also form their own opinion of Boston Scientific's value that differs from its market value or its book value, called intrinsic value, which is Boston Scientific's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Boston Scientific's market value can be influenced by many factors that don't directly affect Boston Scientific's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Boston Scientific's value and its price as these two are different measures arrived at by different means. Investors typically determine if Boston Scientific is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Boston Scientific's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.